GILEAD SCIENCES, INC. Contract with Customer, Performance Obligation Satisfied in Previous Period
GILEAD SCIENCES, INC. (GILD) reported Contract with Customer, Performance Obligation Satisfied in Previous Period of $158.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Revenue from Contract with Customer
us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod · last filed 2026-08-06
- GILEAD SCIENCES, INC. contract with customer, performance obligation satisfied in previous period for the quarter ending 2026-06-30 was $158.00M, a 3.27% increase year-over-year.
- GILEAD SCIENCES, INC. contract with customer, performance obligation satisfied in previous period for the quarter ending 2026-03-31 was $152.00M, a 3.18% decline year-over-year.
- GILEAD SCIENCES, INC. contract with customer, performance obligation satisfied in previous period for the quarter ending 2025-12-31 was $154.00M, a 15.38% decline year-over-year.
- GILEAD SCIENCES, INC. contract with customer, performance obligation satisfied in previous period for the quarter ending 2025-09-30 was $148.00M, a 14.45% decline year-over-year.
- GILEAD SCIENCES, INC. contract with customer, performance obligation satisfied in previous period for fiscal 2025 was $612.00M, a 15.82% decline from fiscal 2024.
- GILEAD SCIENCES, INC. contract with customer, performance obligation satisfied in previous period for fiscal 2024 was $727.00M, a 6.91% increase from fiscal 2023.
- GILEAD SCIENCES, INC. contract with customer, performance obligation satisfied in previous period for fiscal 2023 was $680.00M, a 13.15% decline from fiscal 2022.
- GILEAD SCIENCES, INC. contract with customer, performance obligation satisfied in previous period for fiscal 2022 was $783.00M, a 7.99% decline from fiscal 2021.
| Period end | Contract with Customer, Performance Obligation Satisfied in Previous Period 3 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 3 month as first filed | Contract with Customer, Performance Obligation Satisfied in Previous Period 6 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 6 month as first filed | Contract with Customer, Performance Obligation Satisfied in Previous Period 9 month | Contract with Customer, Performance Obligation Satisfied in Previous Period 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $158.00M 10-Q · filed 2026-08-06 | $310.00M 10-Q · filed 2026-08-06 | $464.00M derived: sum of 3 quarters · filed 2026-08-06 | $612.00M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $152.00M 10-Q · filed 2026-05-07 | $306.00M derived: sum of 2 quarters · filed 2026-05-07 | $454.00M derived: sum of 3 quarters · filed 2026-05-07 | $607.00M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $154.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $302.00M derived: sum of 2 quarters · filed 2026-02-24 | $455.00M derived: sum of 3 quarters · filed 2026-08-06 | $612.00M 10-K · filed 2026-02-24 | ||
| 2025-09-30 | $148.00M 10-Q · filed 2025-11-07 | $301.00M derived: sum of 2 quarters · filed 2026-08-06 | $458.00M 10-Q · filed 2025-11-07 | $640.00M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $153.00M 10-Q · filed 2026-08-06 | $310.00M 10-Q · filed 2026-08-06 | $492.00M derived: sum of 3 quarters · filed 2026-08-06 | $665.00M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $157.00M 10-Q · filed 2026-05-07 | $339.00M derived: sum of 2 quarters · filed 2026-05-07 | $512.00M derived: sum of 3 quarters · filed 2026-05-07 | $714.00M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $182.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $355.00M derived: sum of 2 quarters · filed 2026-02-24 | $557.00M derived: sum of 3 quarters · filed 2026-02-24 | $727.00M 10-K · filed 2026-02-24 | ||
| 2024-09-30 | $173.00M 10-Q · filed 2025-11-07 | $375.00M derived: sum of 2 quarters · filed 2025-11-07 | $545.00M 10-Q · filed 2025-11-07 | $709.00M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-06-30 | $202.00M 10-Q · filed 2025-08-07 | $372.00M 10-Q · filed 2025-08-07 | $536.00M derived: sum of 3 quarters · filed 2026-02-24 | $702.00M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-03-31 | $171.00M 10-Q · filed 2025-05-07 | $334.00M derived: sum of 2 quarters · filed 2026-02-24 | $500.00M derived: sum of 3 quarters · filed 2026-02-24 | $658.00M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2023-12-31 | $163.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $329.00M derived: sum of 2 quarters · filed 2026-02-24 | $487.00M derived: sum of 3 quarters · filed 2026-02-24 | $680.00M 10-K · filed 2026-02-24 | ||
| 2023-09-30 | $166.00M 10-Q · filed 2024-11-12 | $324.00M derived: sum of 2 quarters · filed 2024-11-12 | $517.00M 10-Q · filed 2024-11-12 | $726.00M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-06-30 | $158.00M 10-Q · filed 2024-08-08 | $350.00M 10-Q · filed 2024-08-08 | $560.00M derived: sum of 3 quarters · filed 2025-02-28 | $752.00M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-03-31 | $192.00M 10-Q · filed 2024-05-08 | $402.00M derived: sum of 2 quarters · filed 2025-02-28 | $594.00M derived: sum of 3 quarters · filed 2025-02-28 | $791.00M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2022-12-31 | $210.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $402.00M derived: sum of 2 quarters · filed 2025-02-28 | $599.00M derived: sum of 3 quarters · filed 2025-02-28 | $783.00M 10-K · filed 2025-02-28 | ||
| 2022-09-30 | $192.00M 10-Q · filed 2023-11-07 | $389.00M derived: sum of 2 quarters · filed 2023-11-07 | $573.00M 10-Q · filed 2023-11-07 | $799.00M derived: sum of 4 quarters · filed 2024-02-23 | ||
| 2022-06-30 | $197.00M 10-Q · filed 2023-08-04 | $381.00M 10-Q · filed 2023-08-04 | $607.00M derived: sum of 3 quarters · filed 2024-02-23 | $797.00M derived: sum of 4 quarters · filed 2024-02-23 | ||
| 2022-03-31 | $184.00M 10-Q · filed 2023-05-03 | $410.00M derived: sum of 2 quarters · filed 2024-02-23 | $600.00M derived: sum of 3 quarters · filed 2024-02-23 | $809.00M derived: sum of 4 quarters · filed 2024-02-23 | ||
| 2021-12-31 | $226.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $416.00M derived: sum of 2 quarters · filed 2024-02-23 | $625.00M derived: sum of 3 quarters · filed 2024-02-23 | $851.00M 10-K · filed 2024-02-23 | ||
| 2021-09-30 | $190.00M 10-Q · filed 2022-11-02 | $399.00M derived: sum of 2 quarters · filed 2022-11-02 | $625.00M 10-Q · filed 2022-11-02 | $1.37B derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2021-06-30 | $209.00M 10-Q · filed 2022-08-08 | $435.00M 10-Q · filed 2022-08-08 | $1.18B derived: sum of 3 quarters · filed 2023-02-22 | $1.20B derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2021-03-31 | $226.00M 10-Q · filed 2022-05-04 | $973.00M derived: sum of 2 quarters · filed 2023-02-22 | $986.00M derived: sum of 3 quarters · filed 2023-02-22 | $1.03B derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2020-12-31 | $747.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $760.00M derived: sum of 2 quarters · filed 2023-02-22 | $803.00M derived: sum of 3 quarters · filed 2023-02-22 | $841.00M 10-K · filed 2023-02-22 | ||
| 2020-09-30 | $13.00M 10-Q · filed 2020-11-04 | $56.00M derived: sum of 2 quarters · filed 2020-11-04 | $94.00M 10-Q · filed 2020-11-04 | $526.00M derived: sum of 4 quarters · filed 2022-02-23 | ||
| 2020-06-30 | $43.00M 10-Q · filed 2020-08-06 | $81.00M 10-Q · filed 2020-08-06 | $513.00M derived: sum of 3 quarters · filed 2022-02-23 | $522.00M derived: sum of 4 quarters · filed 2022-02-23 | ||
| 2020-03-31 | $38.00M 10-Q · filed 2020-05-06 | $470.00M derived: sum of 2 quarters · filed 2022-02-23 | $479.00M derived: sum of 3 quarters · filed 2022-02-23 | $672.00M derived: sum of 4 quarters · filed 2022-02-23 | ||
| 2019-12-31 | $432.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $441.00M derived: sum of 2 quarters · filed 2022-02-23 | $634.00M derived: sum of 3 quarters · filed 2022-02-23 | $741.00M 10-K · filed 2022-02-23 | ||
| 2019-09-30 | $9.00M 10-Q · filed 2020-11-04 | $202.00M derived: sum of 2 quarters · filed 2020-11-04 | $309.00M 10-Q · filed 2020-11-04 | $455.00M derived: sum of 4 quarters · filed 2020-11-04 | ||
| 2019-06-30 | $193.00M 10-Q · filed 2020-08-06 | $171.00M 10-Q · filed 2019-08-06 | $300.00M 10-Q · filed 2020-08-06 | $326.00M 10-Q · filed 2019-08-06 | $446.00M derived: sum of 3 quarters · filed 2020-08-06 | $613.00M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $107.00M 10-Q · filed 2020-05-06 | $155.00M 10-Q · filed 2019-05-08 | $253.00M derived: sum of 2 quarters · filed 2020-05-06 | $420.00M derived: sum of 3 quarters · filed 2020-05-06 | $551.00M derived: sum of 4 quarters · filed 2020-05-06 | |
| 2018-12-31 | $146.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $313.00M derived: sum of 2 quarters · filed 2019-02-26 | $444.00M derived: sum of 3 quarters · filed 2019-08-06 | $541.00M 10-K · filed 2019-02-26 | ||
| 2018-09-30 | $167.00M 10-Q · filed 2018-11-06 | $298.00M derived: sum of 2 quarters · filed 2019-08-06 | $395.00M 10-Q · filed 2018-11-06 | |||
| 2018-06-30 | $131.00M 10-Q · filed 2019-08-06 | $222.00M 10-Q · filed 2018-08-06 | $228.00M 10-Q · filed 2019-08-06 | $232.00M 10-Q · filed 2018-08-06 | ||
| 2018-03-31 | $97.00M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |